Sunny Reddy

Sunny joined Aisling in 2019 and serves as a Principal.
Prior to Aisling, Sunny was an Associate and Analyst at SVB Leerink, a healthcare-specialist investment bank, focusing on biopharma/therapeutics.
Prior to SVB Leerink, Sunny was a Quantitative Analyst at Bank of America Merrill Lynch specializing in credit derivative products.
He was also a research associate working in oncology drug development prior to his careers in finance and investing.
Sunny currently serves as a board observer for Forge Biologics, Garuda Therapeutics and Wugen.
His prior board service includes Monte Rosa Therapeutics (observer).
Sunny received his B.S.
in Biomedical Engineering from the Georgia Institute of Technology with high honors and was a HOPE and Zell Miller Scholar recipient.